No data to show
XNAS
LYRA
Market cap15mUSD
Jun 12, Last price
11.85USD
1D
-12.22%
1Q
6,789.53%
IPO
-33.35%
Name
Lyra Therapeutics Inc
Chart & Performance
P/E
—
P/S
10.24
EPS
—
Div Yield, %
—
Shrs. gr., 5y
38.18%
Rev. gr., 5y
4.60%
Revenues
2m
-1.54%
Net income
-93m
L+49.07%
CFO
-70m
L+10.59%
Earnings
Aug 12, 2025
Profile
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 1,534 -1.54% | 1,558 14.31% | 1,363 378.25% | ||||
Cost of revenue | 62,267 | 67,086 | 57,420 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (60,733) | (65,528) | (56,057) | ||||
NOPBT Margin | |||||||
Operating Taxes | 39 | 59 | 13 | ||||
Tax Rate | |||||||
NOPAT | (60,772) | (65,587) | (56,070) | ||||
Net income | (93,435) 49.07% | (62,680) 13.39% | (55,278) 30.34% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 8,818 | 69,242 | 100,495 | ||||
BB yield | -65.61% | -26.53% | -105.85% | ||||
| Debt | |||||||
Debt current | 4,121 | 10,868 | 1,549 | ||||
Long-term debt | 64,639 | 48,328 | 2,883 | ||||
Deferred revenue | 12,136 | 14,077 | |||||
Other long-term liabilities | 11,862 | 14,077 | |||||
Net debt | 28,183 | (43,557) | (94,854) | ||||
| Cash flow | |||||||
Cash from operating activities | (70,011) | (63,304) | (43,385) | ||||
CAPEX | (2,338) | (1,047) | (164) | ||||
Cash from investing activities | 80,305 | (12,584) | (65,006) | ||||
Cash from financing activities | 8,531 | 65,691 | 96,257 | ||||
FCF | (46,824) | (96,397) | (54,678) | ||||
| Balance | |||||||
Cash | 40,577 | 102,753 | 97,894 | ||||
Long term investments | 1,392 | ||||||
Excess cash | 40,500 | 102,675 | 99,218 | ||||
Stockholders' equity | (404,725) | (311,265) | (248,633) | ||||
Invested Capital | 462,561 | 445,136 | 359,757 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 65,114 | 49,804 | 30,236 | ||||
Price | 0.21 -96.06% | 5.24 66.88% | 3.14 -27.98% | ||||
Market cap | 13,440 -94.85% | 260,974 174.88% | 94,940 67.68% | ||||
EV | 41,623 | 217,417 | 86 | ||||
EBITDA | (60,262) | (65,250) | (54,990) | ||||
EV/EBITDA | |||||||
Interest | 524 | ||||||
Interest/NOPBT | |||||||